{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:45:58Z","timestamp":1780447558464,"version":"3.54.1"},"reference-count":45,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K16867"],"award-info":[{"award-number":["19K16867"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","award":["Takeda Science Foundation"],"award-info":[{"award-number":["Takeda Science Foundation"]}],"id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Sebaceous carcinoma and sweat gland carcinoma (malignant tumors with apocrine and eccrine differentiation) are rare malignant skin adnexal tumors that differentiate toward sebaceous gland and eccrine and apocrine glands, respectively. Owing to the rarity of these carcinomas, standard treatments for advanced disease have not been established. Because the prognosis of patients with systemic metastasis is poor, a new treatment for these diseases is eagerly desired. Trophoblast cell surface antigen 2 (TROP2) and sacituzumab govitecan, an antibody\u2013drug conjugate of TROP2, have attracted attention in the treatment of various solid tumors. In the current study, we immunohistochemically investigated TROP2 expression in 14 sebaceous carcinoma and 18 sweat gland carcinoma samples and found strong and relatively homogeneous TROP2 staining in both cancer types. The mean Histoscore, a semi-quantitative scoring ranging from 0 (negative) to 300, was 265.5 in sebaceous carcinoma and 260.0 in sweat gland carcinoma. These observations directly suggest that both sebaceous carcinoma and sweat gland carcinoma could be potentially treated with TROP2-targeted antibody\u2013drug conjugates such as sacituzumab govitecan.<\/jats:p>","DOI":"10.3390\/jcm11030607","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T20:40:18Z","timestamp":1643143218000},"page":"607","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["TROP2 Expression in Sebaceous and Sweat Gland Carcinoma"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2679-8546","authenticated-orcid":false,"given":"Takamichi","family":"Ito","sequence":"first","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8433-6035","authenticated-orcid":false,"given":"Yuka","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Tanegashima","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1068-6873","authenticated-orcid":false,"given":"Maho","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Ichiki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"},{"name":"Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Kaku-Ito","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"ref_1","unstructured":"Elder, D.E., Elenitsas, R., Rosenbach, M., Murphy, G.F., Rubin, A.I., and Xu, X. (2014). Lever\u2019s Histopathology of the Skin, Walters Kluwer Health. [11th ed.]."},{"key":"ref_2","unstructured":"Elder, D.E., Massi, D., Scolyer, R.A., and Willemze, R. (2018). Appendageal tumours. WHO Classification of Skin Tumours, IARC Press. [4th ed.]."},{"key":"ref_3","first-page":"10","article-title":"Toxicarioside O Inhibits Cell Proliferation and Epithelial-Mesenchymal Transition by Downregulation of Trop2 in Lung Cancer Cells","volume":"4","author":"Zheng","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7","article-title":"Human Trop-2 is a tumor-associated calcium signal transducer","volume":"76","author":"Ripani","year":"1998","journal-title":"Int. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.78.8.5147","article-title":"Human trophoblast cell-surface antigens defined by monoclonal antibodies","volume":"78","author":"Lipinski","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","article-title":"High expression of TROP2 correlates with poor prognosis in pancreatic cancer","volume":"99","author":"Fong","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.18632\/oncotarget.6733","article-title":"Trop2 is overexpressed in gastric cancer and predicts poor prognosis","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"28725","DOI":"10.18632\/oncotarget.15647","article-title":"Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes","volume":"8","author":"Inamura","year":"2017","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-05-1961","article-title":"Clinical significance of TROP2 expression in colorectal cancer","volume":"12","author":"Ohmachi","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_10","first-page":"3820","article-title":"TNF-\u03b1 promotes colon cancer cell migration and invasion by upregulating TROP-2","volume":"15","author":"Zhao","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ito, T., Tanegashima, K., Tanaka, Y., Hashimoto, H., Murata, M., Oda, Y., and Kaku-Ito, Y. (2021). Trop2 Expression in Extramammary Paget\u2019s Disease and Normal Skin. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147706"},{"key":"ref_12","first-page":"73","article-title":"The role of Trop2 in prostate cancer: An oncogene, biomarker, and therapeutic target","volume":"9","author":"Shen","year":"2021","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1073\/pnas.1905384117","article-title":"Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1","volume":"117","author":"Hsu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1158\/0008-5472.CAN-12-3266","article-title":"Trop-2 promotes prostate cancer metastasis by modulating \u03b2(1) integrin functions","volume":"73","author":"Trerotola","year":"2013","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1074\/jbc.RA119.008084","article-title":"Trophoblast cell surface antigen 2 (Trop-2) phosphorylation by protein kinase C \u03b1\/\u03b4 (PKC\u03b1\/\u03b4) enhances cell motility","volume":"294","author":"Mori","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1476-4598-9-253","article-title":"Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway","volume":"9","author":"Cubas","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/onc.2012.36","article-title":"Upregulation of Trop-2 quantitatively stimulates human cancer growth","volume":"32","author":"Trerotola","year":"2013","journal-title":"Oncogene"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/onc.2012.151","article-title":"The Trop-2 signaling network in cancer growth","volume":"32","author":"Guerra","year":"2013","journal-title":"Oncogene"},{"key":"ref_19","first-page":"759","article-title":"Trop2 is a potential biomarker for the promotion of EMT in human breast cancer","volume":"40","author":"Zhao","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbrc.2016.01.032","article-title":"TROP2 overexpression promotes proliferation and invasion of lung adenocarcinoma cells","volume":"470","author":"Li","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1158\/1078-0432.CCR-17-0933","article-title":"Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan","volume":"23","author":"Gray","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan","volume":"35","author":"Heist","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.clgc.2015.10.002","article-title":"Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma","volume":"14","author":"Faltas","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: Final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Murata, M., Ito, T., Tanaka, Y., Yamamura, K., Furue, K., and Furue, M. (2020). OVOL2-mediated ZEB1 downregulation may prevent promotion of actinic keratosis to cutaneous squamous cell carcinoma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9030618"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/modpathol.2016.169","article-title":"Potential role of the OVOL1-OVOL2 axis and c-Myc in the progression of cutaneous squamous cell carcinoma","volume":"30","author":"Ito","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ajpath.2015.12.013","article-title":"Activation of the OVOL1-OVOL2 Axis in the Hair Bulb and in Pilomatricoma","volume":"186","author":"Ito","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_29","first-page":"3545","article-title":"Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer","volume":"50","author":"McClelland","year":"1990","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: A look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"33658","DOI":"10.1038\/srep33658","article-title":"Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis","volume":"6","author":"Zeng","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Tanaka, Y., Murata, M., Shen, C.H., Furue, M., and Ito, T. (2021). NECTIN4: A Novel Therapeutic Target for Melanoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020976"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tanaka, Y., Murata, M., Oda, Y., Furue, M., and Ito, T. (2021). Nectin Cell Adhesion Molecule 4 (NECTIN4) Expression in Cutaneous Squamous Cell Carcinoma: A New Therapeutic Target?. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040355"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Murata, M., Ito, T., Tanaka, Y., Kaku-Ito, Y., and Furue, M. (2020). NECTIN4 Expression in Extramammary Paget\u2019s Disease: Implication of a New Therapeutic Target. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165891"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00403-019-01971-4","article-title":"Sebaceous carcinoma: Controversies and their evidence for clinical practice","volume":"312","author":"Kibbi","year":"2020","journal-title":"Arch. Dermatol. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1016\/S1470-2045(19)30673-4","article-title":"Sebaceous carcinoma: Evidence-based clinical practice guidelines","volume":"20","author":"Owen","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41379-019-0377-7","article-title":"Do not break a sweat: Avoiding pitfalls in the diagnosis of sweat gland tumors","volume":"33","author":"Brenn","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1002\/hed.26178","article-title":"Eccrine porocarcinoma of the head and neck: Meta-analysis of 120 cases","volume":"42","author":"Le","year":"2020","journal-title":"Head Neck"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.amsu.2017.06.027","article-title":"Porocarcinoma; presentation and management, a meta-analysis of 453 cases","volume":"20","author":"Salih","year":"2017","journal-title":"Ann. Med. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s12105-021-01325-5","article-title":"Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target","volume":"15","author":"Wolber","year":"2021","journal-title":"Head Neck Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"47052","DOI":"10.18632\/oncotarget.16789","article-title":"TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K\/AKT pathway and inducing EMT","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41419-017-0029-0","article-title":"Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma","volume":"9","author":"Redlich","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7781","DOI":"10.1002\/cam4.2658","article-title":"Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody","volume":"8","author":"Nishimura","year":"2019","journal-title":"Cancer Med."},{"key":"ref_44","first-page":"515","article-title":"Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells","volume":"53","author":"Zhang","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/3\/607\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:07:32Z","timestamp":1760134052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/3\/607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["jcm11030607"],"URL":"https:\/\/doi.org\/10.3390\/jcm11030607","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]}}}